 |
|
|
| |
Factors Associated with Healthcare Providers' Preference for Forgoing an Oral Lead-in Phase
when Initiating Long-acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial
|
| |
| |
AIDS 2022 July 29-Aug 1 Montreal
Tahilin Sanchez Karver1,2, Miguel Pascual-Bernaldez3,Alessandro Berni4,Ahmed Hnoosh5,Antonella Castagna6, Peter Messiaen7, Maria Jose Galindo Puerto8, Mark Bloch9, Eisuke Adachi10, Gary Sinclair11, Franco Felizarta12, Jonathan B.Angel13,
Kenneth Sutton14, Denise Sutherland-Phillips14, Ronald D'Amico14, Deanna Kerrigan1
1 George Washington University Milken Institute of Public Health,Washington, D.C., United States; 2 Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States; 3ViiV Healthcare, Madrid, Spain; 4GlaxoSmithKline,West Uxbridge, United Kingdom
5ViiV Healthcare, Brentford, United Kingdom; 6IRCCS San Raffaele Hospital, Milan, Italy; 7Department of Infectious Diseases and Immunity, Jessa Hospital, Hasselt, Belgium; 8Universitat de València,Valencia, Spain; 9Holdsworth House Medical Practice, Sydney,Australia; 10Hospital of the
Institute of Medical Science, University of Tokyo,Tokyo, Japan; 11PrismHealth North Texas, Dallas,Texas, United States; 12Private Practice, Bakersfield, United States; 13The Ottawa Hospital, Ottawa, Canada; 14ViiV Healthcare, Research
|
| |
|
|
|
|
|
